医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

EOS imaging Announces New Installation at a Leading Hospital in Japan

2015年11月05日 AM02:55
このエントリーをはてなブックマークに追加


 

PARIS

EOS imaging (Paris:EOSI)(Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, announced today a new installation of the EOS system at Kudanzaka Hospital, providing an exciting opportunity for the platform to benefit more than 1,000 patients per year who undergo spine surgeries in Japan. The EOS system will be housed in a new building located in the immediate vicinity of the Imperial Palace in Tokyo, which will open to patients on November 24, 2015.

Kudanzaka Hospital is associated with the Tokyo Medical University. It was founded in 1926 and began focusing on the spine in 1980. Over the past 25 years, it has continued to increase the number of complex spine and spinal cord surgeries, with a growing reputation for excellence in the treatment of spinal disorders. With the increased demand, the Kudanzaka Hospital is now expanding its facilities by adding additional cutting edge technologies for treating spine disorders, such as the EOS system.

EOS systems are already in clinical use in Japan at Meijo Hospital, the leading Japanese scoliosis center, as well as in other prominent spine and large joint surgery centers in the country. Marie Meynadier, CEO of EOS imaging said, “As the importance of sagittal balance and global posture restoration continues to be established as key for spine surgery, the EOS system becomes an obvious choice for hospitals because it provides a full-body, weight-bearing scan and 3D clinical parameters. The fact that the two leading spine centers in Japan have adopted the EOS technology is a positive indication that the Japanese healthcare community prioritizes excellence in orthopaedic imaging coupled with a drastic reduction of the risks associated with medical imaging irradiation.”

The EOS platform provides 2D and 3D full-body, stereo-radiographic images of patients in functional positions. EOS exams require a radiation dose 50% to 85% less than Digital Radiology and 95% less than basic CT scans. The new EOS Micro Dose system, recently cleared by the Food and Drug Administration, marks another important step towards the ALARA principle (As Low As Reasonably Available). This latest technology has made the dose for a pediatric spine follow-up exam equivalent to a week’s worth of natural background radiation on Earth.

For more information, please visit www.eos-imaging.com.

EOS imaging has been chosen to be included in the new EnterNext© PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.

EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI

About EOS imaging

EOS imaging designs, develops, and markets EOS®, an innovative medical imaging system dedicated to osteoarticular pathologies and orthopaedics, as well as associated solutions. The Company is authorized to market in 48 countries, including the United States (FDA), Japan and the European Union (EC). The Group posted 2014 revenues of €20.1 million and employs 107 people including an R&D team of 39 engineers. The Group is based in Paris and has five subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada), Frankfurt (Germany) and Singapore.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151104006406/en/

CONTACT

EOS imaging
Anne Renevot
CFO
Ph: +33 (0)1
55 25 61 24
investors@eos-imaging.com
or
NewCap
Financial
communication and investor relations
Pierre Laurent
Ph: +33
(0)1 44 71 94 91
eosimaging@newcap.fr
or
The
Ruth Group (US)

Press relations / Joanna Zimmerman
Ph:
646-536-7006
jzimmerman@theruthgroup.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Clover Biopharmaceuticals Completes RMB 62.8 Million Series A Financing
  • 三叶草生物制药完成6,280万元人民币A轮融资
  • Corindus Announces First Commercial Installation of CorPath® GRX System Outside of U.S.
  • Walmart, JD.com, IBM and Tsinghua University Launch a Blockchain Food Safety Alliance in China
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表